Distinguished in Scleroderma

Dorota M. Krasowska

Staszica 11 St, 
Lublin, LU, PL 
Distinguished in Scleroderma
Staszica 11 St, 
Lublin, LU, PL 
OverviewLocationsClinical Research

Overview

Dorota Krasowska practices in Lublin, Poland. Ms. Krasowska is rated as a Distinguished expert by MediFind in the treatment of Scleroderma. Her top areas of expertise are Scleroderma, Systemic Sclerosis (SSc), Psoriasis, Hives, and Synovectomy.

Her clinical research consists of co-authoring 136 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 32 articles and participated in 1 clinical trial in the study of Scleroderma.

Gender
Female

Locations

Staszica 11 St, Lublin, LU 20081, Poland

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin)
A Long-term Study to Assess the Safety and Efficacy of Lebrikizumab in Patients With Moderate-to-Severe Atopic Dermatitis (ADjoin)
Enrollment Status: Completed
Publish Date: August 03, 2025
Intervention Type: Biological
Study Drug: Lebrikizumab
Study Phase: Phase 3
An Open-Label, Single-Arm Study to Assess the Safety and Efficacy of Lebrikizumab in Adolescent Patients With Moderate-to-Severe Atopic Dermatitis
An Open-Label, Single-Arm Study to Assess the Safety and Efficacy of Lebrikizumab in Adolescent Patients With Moderate-to-Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: February 24, 2023
Intervention Type: Biological
Study Drug: Lebrikizumab
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate Efficacy and Safety of Lenabasum in Diffuse Cutaneous Systemic Sclerosis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate Efficacy and Safety of Lenabasum in Diffuse Cutaneous Systemic Sclerosis
Enrollment Status: Terminated
Publish Date: March 29, 2021
Intervention Type: Drug, Other
Study Phase: Phase 3
View 2 Less Clinical Trials

136 Total Publications

Aberrant Expression of BTLA, CD160, SPN, TIM-3, VISTA and TIGIT in Chronic Lymphocytic Leukemia and Psoriasis Patients Compared to Healthy Volunteers.
Aberrant Expression of BTLA, CD160, SPN, TIM-3, VISTA and TIGIT in Chronic Lymphocytic Leukemia and Psoriasis Patients Compared to Healthy Volunteers.
Journal: Cancers
Published: May 29, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Krasowska's expertise for a condition
ConditionClose
    View All 8 Advanced Conditions
    View All 46 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile